anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: organic chemistry, antibiotics, pharmacy. SUBSTANCE: invention relates to new antibiotics of carbapenem group and their nontoxic pharmaceutically acceptable salts exhibiting antibacterial activity. They can be used both separately and in combination with other antibiotics for treatment of human and animals with bacterial infections. Compounds of the formula (I)   where moiety -S-  means 5-membered heterocyclic substituted ring where: (A) Z means oxygen, sulfur atom; (B) R 0  means -CH(OR 4 )CH 3  where R 4  means hydrogen atom; (C) R 1  means (C 1 -C 3 )-alkyl. Substituents of a group -S-  are taken from (CH 2 ) n R 2  where: (D) n is a whole number from 0 to 4; (E) R 2  means: (1) methyl-group, bromine, chlorine, iodine atom, -OSO 2 CH 3 , azido-group; (II) a group of the formula -S(O) n ″R a  where n'' is a whole number from 0 to 2; R a  means a group bound by carbon atom and taken from substituted or nonsubstituted (C 1 -C 6 )-alkyl, substituted or nonsubstituted phenyl, substituted or nonsubstituted phenyl-(C 1 -C 6 )-alkyl being chlorine, bromine atoms and hydroxy-group can be substituents; (III) R 2  is taken from hydroxy-group, OR a , OC(O)NR a R a  where R a  means independently values indicated above or   where R 13  means   and B -  is a physiologically acceptable anion; (IV) or R 2  means a residue bound by nitrogen atom and means: formula (a)   where R p  means oxygen atom; R L  and R J  mean independently hydrogen atom, alkyl, substituted or nonsubstituted amine, heterocycle where heterocycle means 5- or 6-membered ring containing two atoms N or O; or R L  and R J  with the bound nitrogen atom form nonsubstituted monocyclic ring containing two heteroatoms taken independently form O or N being substituents are hydroxyl, oxo-group; (b) acyclic quaternary ammonium group of the formula:   where R 7 , R 8 , R 9  mean alkyl; B -  is a physiologically acceptable anion; (V) or R 2  means a group bound by carbon atom and has a formula:   where R 2  and R 3  are indicated above, and pharmaceutical acceptable salts of the compound described. Invention relates to also a method of synthesis of antibiotics of carbapenem group and some intermediate compounds. Invention proposes methods of treatment of human and animals with infectious diseases that involve administration of the above indicated compounds to human or animals and pharmaceutical preparations containing these compounds. EFFECT: improved method of synthesis and treatment. 6 cl, 14 dwg, 409 ex
It is intended to search for and provide a novel gene participating in multiple tolerance in cancer and its protein. It is also intended to clarify the functions of the gene and the protein and to provide a method of examining the gene and an antibody against the protein. It is further intended to provide a method of examining and diagnosing cancer by using the above gene and antibody. Thus, a novel protein (RB1CC1) or a polypeptide, which occurs in the nucleus of a human or animal cell and has a transcriptional function and/or a function of inducing the expression of retinoblastoma-1 gene (RB1 gene) or its gene product, and its gene are found out. Then the amino acid sequence and the cDNA sequence thereof are determined and the gene is amplified and detected with the use of primers hybridizable with the novel gene. Thus, the expression, mutation, etc. of the novel gene are examined and the relationship thereof with the proliferation of cancer cells is found out, thereby examining cancer. An antibody against the novel protein is prepared and the novel protein is detected by using the antibody. Thus, the relationship between the novel protein and the proliferation of cancer cells is found out, thereby examining cancer.
Systems and processes for assembling de-itendified patient healthcare data records in a longitudinal database are provided. The systems and processes may be implemented over multiple data suppliers and common database facilities while ensuring patient privacy. At the data supplier locations, patient-identifying attributes in the dtaa records are placed in standard format and then doubly encrypted using a pair of encryption keys before transmission to a common database facility. The pair of encryption keys includes a key specific to the data supplier and a key specific to the common database facility. At the common database facility, the encryption specific to the data supplier is removed, so that multi-sourced data records have only the common database encryption. Without direct access to patient identifying-information, the encrypted data records assigned dummy labels or tags by which the data records can be longitudinally linked in the database. The tags are assigned based on statistical matching of the values of a select set of encrypted data attributes with a reference database of tags and associated encrypted data attribute values.
BACKGROUND: Painful, treatment-resistant wounds are prevalent among diabetic patients and significantly affect health-related quality of life (HRQOL). Topical treatments may help alleviate pain without risk of dependence or side effects. However, there is a lack of topical wound compounds targeting pain-specific receptors. One possible target is proinflammatory angiotensin 1 receptor (AT1R), which is upregulated in diabetic skin and has been implicated in nociception.
OBJECTIVES: We investigated the effects of topical valsartan, an AT1R antagonist, on pain (nociceptive thresholds) and gene expression changes (transcriptomics) in a swine model of diabetic wounds.
METHODS: Eight wounds were surgically induced in diabetic, hyperglycemic Yucatan miniature swine ( n = 4). Topical AT1R antagonist was applied to wounds on one side and vehicle on the other side. Nocifensive testing was conducted at baseline and then weekly, beginning 7 days after wound induction. Mechanical and thermal stimuli were applied to the wound margins until a nocifensive reaction was elicited or a predetermined cutoff was reached. After 7 weeks of testing, tissue from the dorsal horn, dorsal root ganglion, and wounds were sequenced and analyzed with DESeq2. Unbiased pathway analyses using Metascape were conducted on differentially expressed genes.
RESULTS: There was no significant difference in mechanical tolerance threshold between AT1R antagonist-treated and vehicle-treated wounds ( p = .106). Thermal tolerance was significantly higher in AT1R antagonist-treated wounds compared to vehicle-treated ( p = .015). Analysis of differentially expressed genes revealed enriched pathways of interest: interleukin-18 signaling in dorsal horn laminae IV-V and sensory perception of mechanical stimulus in wound tissue.
DISCUSSION: In this study, wounds modeling diabetic ulcers were created in hyperglycemic swine and treated with a topical AT1R antagonist. AT1R-antagonist-treated wounds had a higher tolerance threshold than vehicle-treated wounds for thermal hyperalgesia, but not mechanical allodynia. Pathway analyses of differentially expressed genes revealed several pathways of interest for future pain research. Although further studies are needed to confirm the findings, this study can improve nursing care by providing information about a potential future treatment that may be used to decrease pain and improve HRQOL in patients with diabetic wounds.
This pilot study will enrol 70 WLWH aged 25-64, with no history of cervical abnormalities attending 4 HIV clinics in the UK. Participants will be asked to complete an entry survey in which behavioural information, gynaecological and sexual history, will be collected, with the aim of characterising the study population for the risk factors of HPV infection. Women's attitude towards the current cervical screening and their view on a change to HPV testing will also be assessed. Participants' relevant clinical data will be collected form their medical notes. Women will be instructed to perform a self-taken vaginal swab for the detection of HR HPV while in clinic, and they will be reminded of the annual cervical smear (which can be offered in clinic or performed at their GP practice as per local policy). After six months, women will be asked to take another vaginal swab; this can be offered in clinic, during the regular HIV follow up, or can be sent via the post. Another sample for HR-HPV testing will be collected one year later, at the next routine HIV appointment. The annual smear test will be due and this will be offered in clinic or done at the GP practice, according to local policies. After this visit, an exit questionnaire will be undertaken to evaluate the acceptability of the study procedures.
BACKGROUND: Occult blood in the urine, or microhematuria, is a common finding (about 10%) in children and young adults. It is often of brief duration and therefore harmless. In persistent microhematuria, acanthocytes in the urine are a frequently unrecognized early marker of glomerular kidney disease. The purpose of this guideline is to promote the early detection of kidney disease in children and young adults with practical, evidence-based recommendations.
METHODS: A systematic search for pertinent publications up to January 2023 was conducted in Pubmed, the Cochrane Database, and Livivo. 474 publications were retrieved, summarized in terms of method and content, and classified by Oxford (2011) evidence level.
RESULTS: Approximately 1% of children and young adults have undiagnosed chronic kidney disease. Microhematuria is an early warning sign. A timely nephrological evaluation is indicated if microhematuria persists for 3 to 6 months, if ≥ 5% acanthocytes are detectable in the urine, and if there is also proteinuria, hypertension, or impaired renal function. Ultrasonography of the kidneys and urinary tract is the imaging method of choice; cystoscopy should be avoided. For patients with glomerular microhematuria, molecular genetic testing is recommended. Renal biopsy is recommended in case of florid glomerular diseases, after the determination of various laboratory param eters and clinical findings, including molecular genet ic testing especially in children.
CONCLUSION: In the absence of a guideline until now, findings have often been incorrectly assessed, leading either to an inadequate work-up or to excessive diagnostics. As a result, in approximately 30% of young patients, valuable opportunities for early treatment to protect the kidneys have been missed.
Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
PURPOSE: To provide a transcutaneous drug delivery system having a single layer form and suitable for the administration of a preparatorily defined controlled amount of a drug to the skin or mucosa of mammal over a long period. CONSTITUTION: This drug delivery system is a patch composed of a single substance of an elastomer matrix having prescribed thickness and area and containing an active drug component and a diffusion accelerator uniformly dispersed over the whole area. The active drug component is preferably an adrenomimetic agent (especially albuterol) or a selective β2 -adrenomimetic agent and the diffusion accelerator is preferably n-hydrocarbon alcohol, especially n-dodecanol. The elastomer matrix may further contain a plasticizer, a solubilizer and a curing catalyst and is preferably composed of a silicone rubber, glycerol, n-hexanol and an organic tin catalyst. The patch contains e.g. 45-95 wt.% of an elastomer matrix, 2-30 wt.% of albuterol and 3-30 wt.% of n- dodecanol.
Social determinants of health are known to underly excessive burden from infectious diseases. However, it is unclear if social determinants are strong enough drivers to cause repeated infectious disease clusters in the same location. When infectious diseases are known to co-occur, such as in the co-occurrence of HIV and TB, it is also unknown how much social determinants of health can shift or intensify the co-occurrence. We collected available data on COVID-19, HIV, influenza, and TB by county in the United States from 2019-2022. We applied the Kulldorff scan statistic to examine the relative risk of each disease by year depending on the data available. Additional analyses using the percent of the county that is below the US poverty level as a covariate were conducted to examine how much clustering is associated with poverty levels. There were three counties identified at the centers of clusters in both the adjusted and unadjusted analysis. In the poverty-adjusted analysis, we found a general shift of infectious disease burden from urban to rural clusters.
The overall goal of this project is to compare the effectiveness of high intense periodic and usual weekly therapy in treating Cerebral Palsy (CP) in children 2-8 years of age for motor rehabilitation. In this prospective randomized controlled trial (RCT), 108 children ages 2 to 8 years of age with CP will be enrolled and assigned to one of 2 service delivery models: 1 hour per day, 1 x per week for 40 weeks (usual weekly); and 2 hours every weekday for two 10-consecutive-weekdays (total 4 weeks), for a repeated "periodic" bout (high intense periodic). Participants unable to consent to randomization are allowed to chose a treatment group. All patients enrolled in ACHIEVE will also have 1 hour per month of Physical Therapy Consultation (PTC) during the treatment period of 40 weeks (9 months). PTCs provide monthly motor skill monitoring, consultation, and home therapy program progression. Outcome evaluations will be performed by blinded evaluators at baseline (month 0, before treatment), month 9 for all patients to assess short term effects, and at months 12 and 18 for patients to assess long term effects. Parent surveys will be collected at 0, 4.5, and 9 months only (PC-2). Short-term and long-term effects will be analyzed to determine individual differences in children's response to intensity. A subset will be analyzed at 12 and 18 month.
FIELD: veterinary science, microbiology. SUBSTANCE: mixed vaccine has viral and bacterial components balanced with antigenic and immunogenic relationship. Among plague viruses of carnivores vaccine has cultural viral suspension of the strain Virus distemper canine ЭПМ with titer of infectious activity 10 3 -10 4  TCD/0.5 ml. Among salmonella antigens vaccine has cell suspensions of strains Salmonella typhimurium N 3, Salmonella dublin N 6, Salmonella cholerasuis N 9. Concentration of each strain is 10 billion cells/1 ml of physiological solution. Vaccine has stabilizing agent also. Mixed vaccine shows enhanced antigenic and immunogenic activity. Mixed vaccine can be used for specific prophylaxis of carnivorous plague and salmonellosis in foxes and polar foxes. EFFECT: enhanced effectiveness of vaccine. 2 cl, 5 tbl, 4 ex
Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
Tryptophan (Trp) has been shown to regulate immune function by modulating gut serotonin (5-HT) metabolism and signaling. However, the mechanisms underlying the microbial modulation of gut 5-HT signaling in gut inflammation with gut microbiota dysbiosis require further investigation. Here, we investigated the effects of Trp supplementation on the composition and metabolism of the gut microbiome and 5-HT signaling-related gut immune function using a dextran sodium sulfate (DSS)-induced colitis mouse model coupled with antibiotic exposure. The results showed that antibiotic treatment before but not during DSS treatment decreased the immunoregulatory effects of Trp and aggravated gut inflammation and body weight loss in mice. Metagenomic analysis revealed that the fecal microbiota transplantation of Trp-enriched gut microbiota to recipient mice subject to antibiotic pre-exposure and DSS treatment alleviated inflammation by increasing the relative abundances of Lactobacillus and Parabacteroides and the microbial production of indole coupled with the activation of the 5-HT receptor 2B (HTR2B) in the colon. Transcriptomic analysis showed that HTR2B agonist administration strengthened the beneficial effects of Trp in DSS-induced colitis mice with antibiotic exposure by reducing gut lipopolysaccharide-binding protein (LBP) production, IκB-α/nuclear factor-κB signaling, and M1 macrophage polarization. Indole treatment reduced LBP production and M1 macrophage polarization both in mice with DSS-induced colitis and in lipopolysaccharide-treated mouse macrophages; however, the HTR2B antagonist reversed the effects of indole. Our findings provide the basis for developing new dietary and therapeutic interventions to improve gut microbiota dysbiosis-associated inflammatory gut disorders and diseases.
Various areas of photo-triggered drug release and photoreaction include reactions that are typically based on triplet-triplet energy transfer with long wavelength photoexcitation. Systems and methods for absorbing energy in a photosensitizer, and methods for making or using such systems, kits comprising such systems. The systems and methods include transferring this energy by triplet-triplet energy transfer to cleave a cleavable or other active moiety, e.g., to cause release of a releasable moiety. In some cases, these may be contained in a suitable carrier material, such as a particle or micelle. Such systems and methods may be used in a variety of applications, including various biological or physical applications. For example, such systems and methods may be used to deliver a drug or other releasable moiety to an area of a subject.
The present invention relates to intercalator pseudonucleotides. Intercalator pseudonucleotides according to the invention are capable of being incorporated into the backbone of a nucleic acid or nucleic acid analogue and they comprise an intercalator comprising a flat conjugated system capable of co-stacking with nucleobases of DNA. The invention also relates to oligonucleotides or oligonucleotide analogues comprising at least one intercalator pseudo nucleotide. The invention furthermore relates to methods of synthesising intercalator pseudo nucleotides and methods of synthesising oligonucleotides or oligonucleotide analogues comprising at least one intercalator pseudonucleotide. In addtition, the invention describes methods of separating sequence specific DNA(s) from a mixture comprising nucleic acids, methods of detecting a sequence specific DNA (target DNA) in a mixture comprising nucleic acids and/or nucleic acid analogues and methods of detecting a sequence specific RNA in a mixture comprising nucleic acids and/or nucleic acid analogues. In particular said methods may involve the use of oligonucleotides comprising intercalator pseudo nucleotides. The invention furthermore relates to pairs of oligonucleotides or oligonucleotide analogues capable of hybridising to one another, wherein said pairs comprise at least one intercalator pseudonucleotide. Methods for inhibiting a DNAse and/or a RNAse and methods of modulating transcription of one or more specific genes are also described.
Patients who are suspected to have DCIS based on mammographic findings will be invited to participate in this study. The investigators plan to recruit 200 patients who are scheduled to undergo a breast biopsy for a breast lesion considered suggestive or highly suggestive of DCIS as determined by a radiologist specializing in breast imaging. Each patient will have a suspicious area of calcification on mammography of extent \< 3 cm, or a non-focal area of abnormality on ultrasound or MRI that is scheduled for evaluation by biopsy. Each patient will undergo an MBI study immediately prior to biopsy. The study coordinator will approach these patients and inform them of the research project. If they are interested in participating, informed consent will be obtained and the patient will be scheduled for the MBI study prior to the breast biopsy.
Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.
The patients will receive laparoscopic or robotic assisted radical hysterectomy with improved surgery details: 1) Uterine manipulator type Cup-shaped uterine manipulator is prohibited, uterus hanging wire is allowed. 2) Avoid tumor cells shedding into the pelvis: A. Cut the vagina with the transvaginal method, B. Cut the vagina after closed loop ligation of the vagina. After the surgery, they will receive adjuvant therapy according to the pathological risk factors refer to the 2018 NCCN guidelines.
Methods and compositions for increasing trichogenicity of cells in culture are provided. One embodiment provides culturing dissociated mammalian dermal cells in vitro in the presence of an effective amount of one or more sonic hedgehog (Shh) pathway agonists to increase the trichogenicity of the dissociated mammalian dermal cells compared to untreated dissociated mammalian dermal cells. The cell culture optionally includes epidermal cells. Preferred Shh agonists include, but are not limited to CUR-0236715 and CUR-0201365 available from Curis, Inc. Trichogenicity is measured using the Aderans Hair Patch Assay™. The cultured dermal cells can be maintained in culture in the presence of the one or more Shh agonists for at least 1 to 7 or more days prior to harvest. The treated, cultured dermal cells can be used to treat hair loss in a mammalian subject, preferably a human, by implanting them in an effective amount to induce hair follicle formation.